IPO could value Pfizer's Zoetis at up to $12.5 billion
(Reuters) - Pfizer Inc's unit Zoetis Inc plans to sell 86.1 million shares at between $22 and $25 each in an initial public offering that could value the animal health business at as much as $12.5 billion.
At the top-end of the expected range, the offering would raise about $2.2 billion.
The Wall Street Journal reported last month that the Zoetis IPO was likely by January or February, and that it could raise about $4 billion.
Pfizer said in June last year that it planned to separate its animal-health unit, which sells medicines, vaccines and other products for livestock and pets, into a standalone company.
The unit reported revenue of $3.16 billion, or about 7 percent of Pfizer's overall revenue, for the nine months ended September 30, 2012.
Zoetis had filed with regulators in August a placeholder amount of up to $100 million, as the largest U.S. drugmaker looked to spin off the unit and narrow its focus on its core prescription drug business.
Zoetis will use a dual-class share structure, with Pfizer offering all the Class A common shares in the IPO.
Pfizer will hold 413.9 million Class B Zoetis shares following the offering, each of which would be convertible to one Class A share at any time, according to an amended regulatory filing. (link.reuters.com/fyt35t)
Both classes of shares will have identical rights and voting power on all matters submitted to stockholder vote, other than the election of directors.
The Zoetis IPO is scheduled to price on January 31 and shares are expected to begin trading under the symbol "ZTS" on the New York Stock Exchange on February 1.
JP Morgan, BofA Merrill Lynch and Morgan Stanley are the lead underwriters to the offering.
(Reporting by Ashutosh Pandey and Aman Shah in Bangalore; Editing by Roshni Menon)
- Tweet this
- Share this
- Digg this
- Malaysia military tracked missing plane to west coast - source
- Rupee falls after sources say plan to join global debt index on hold
- UPDATE 5-GM hires law firms it works with to probe recall response
- Malaysia air probe finds scant evidence of attack - sources
- India halts plan to join global bond indexes, defers Euroclear - sources
Made by local firm Lomus Pharmaceuticals and backed by the government, the U.S. aid agency and other donors, "Navi Malam" gel was introduced in 2011 in hospitals across Nepal and has helped to reduce the number of babies dying from umbilical cord infection. Trials have shown a 23 percent drop in newborn deaths due to infection since the gel was introduced, according to USAID. Full Article